Help improve cancer early detection
You are invited to join the PATHFINDER study
Too often, cancer goes undetected until it is at an advanced stage. Thinking about the possibility of having cancer can feel overwhelming, but taking steps to catch cancer early can make you feel more in control of your health. The earlier that cancer can be found, the higher the chance of survival.
A blood test designed to detect multiple types of cancer
The PATHFINDER study will evaluate GRAIL’s multi-cancer early detection test, an investigational test that has been designed to detect many types of cancer through one blood draw. The U.S. Food and Drug Administration has not yet approved this test for use outside of a research study. It is not meant to replace the cancer screening tests your healthcare provider may recommend, such as colonoscopy or mammography.
The test looks for signals of cancer that may be present in a person’s blood. If a signal that may be cancer is detected, the test is designed to identify the location in the body the signal may be coming from, for example, the lungs or the colon. This information helps healthcare providers determine the appropriate tests to confirm whether cancer is present. GRAIL’s multi-cancer early detection test does not measure your genetic risk of developing cancer in the future.
OHSU is one of five national study sites
The OHSU Knight Cancer Institute is one of five sites across the country selected by GRAIL, Inc., a health care company dedicated to detecting cancer early, to join a study designed to improve early detection of cancer. The PATHFINDER Study is locally overseen by Tom Beer, M.D., deputy director of the OHSU Knight Cancer Institute.
Who can participate?
Participation in the PATHFIDNER study is voluntary and is currently open to men and women aged 50 years or older who meet eligibility criteria and receive care at OHSU or other participating health systems. As a participant of the study, you will receive your test results.
What does study participation involve?
Participants will be asked to:
- Read and sign an informed consent form that fully explains the study
- Provide their medical history and complete an initial questionnaire
- Provide a blood sample (4 tubes) drawn by a trained practitioner
- Complete additional questionnaires during the follow-up period
Visit the PATHFINDER study website for complete details.
How to enroll in the PATHFINDER study
To find out if you are eligible to enroll or if you have questions, contact a study coordinator:
- 503 418-8150
CAUTION: GRAIL’s multi-cancer early detection test is an investigational device. Limited by Federal law to investigational use.